Head-to-head evidence
Aclidinium bromide/formoterol fumarate vs Umeclidinium
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Obstructive Pulmonary Disease
Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Chronic Obstructive Pulmonary Disease pipeline
Aclidinium bromide/formoterol fumarate · Duaklir Pressair
Marketed by Covis Pharma
NCT01437397 · Phase 3 · completed
This was a large randomized, quadruple-blind, placebo- and active-controlled trial with 1,692 randomized participants, using the regulator-accepted clinical lung-function measure FEV1 as its primary endpoint. Results were mixed: the 400/12 μg combination significantly improved post-dose FEV1 versus aclidinium and trough FEV1 versus formoterol, whereas the 400/6 μg combination did not significantly improve trough FEV1 versus formoterol (p=0.133).
Umeclidinium · Incruse Ellipta
Marketed by GlaxoSmithKline
NCT02184611 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial in 308 patients using lung function (trough FEV1) as its primary measure, and umeclidinium produced a significantly greater improvement than placebo (least-squares mean difference 0.154 L, 95% CI 0.113 to 0.194, p<0.001).
Next expected readout: December 2026 · NCT07133880 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aclidinium bromide/formoterol fumarate's landscape · Umeclidinium's landscape